Clinical trial

Beta 3 Agonist Treatment in Heart Failure-2

NCT03926754

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-01-23

PhasePHASE2 / PHASE3

Study timeline

Study start (actual)2017-01-23Date precision: day

Registry last updated2022-05-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Heart Failure With Reduced Ejection Fraction NYHA Class III-IVunresolved

Interventions

MirabegronDRUG · verified · RxNorm: mirabegron

Sponsors & collaborators

Henning Bundgaardlead sponsor

University Hospital Bispebjerg and Frederiksbergcollaborator

Hillerød hospital, Denmarkcollaborator

Herlev Hospitalcollaborator

Hvidovre University Hospitalcollaborator

Bornholm Hospital, Denmarkcollaborator

Royal North Shore Hospitalcollaborator

Mapped research locations

CopenhagenDenmark1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03926754 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.